CD19 and acute lymphoblastic leukemia: In a recent trial by the UCART19 group, genome-edited, donor-derived allogeneic anti-CD19 CAR-T cells were given to adults and children with refractory B-ALL after FluCy conditioning with or without alemtuzumab.